
Lilly rides GLP-1 wave, lifts 2026 outlook on Zepbound/Mounjaro demand
Eli Lilly beat Q2 estimates as demand for obesity and diabetes drugs fueled stronger earnings, prompting a raise in 2026 revenue guidance to $85–$87 billion. Q2 revenue was $22.97 billion with adjusted EPS of $8.38; Mounjaro worldwide sales reached $9.94 billion, Zepbound US sales were $4.93 billion, and Foundayo contributed $98 million in its first quarter of selling. International sales surged while price cuts trimmed some gains. The company highlighted ongoing aggressive M&A activity and expected benefits from Medicare coverage for obesity drugs.











